<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702607</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 18520</org_study_id>
    <nct_id>NCT04702607</nct_id>
  </id_info>
  <brief_title>Functional Lung Imaging With DECT and 4DCT</brief_title>
  <official_title>Pilot Study to Assess Lung Function Using Perfusion Blood Volume Dual Energy CT and 4DCT Derived Lung Ventilation Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The basic premise of this pilot study is to enroll 40 patients over 1.5 years who have Stage&#xD;
      III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent&#xD;
      chemoradiation where a contrast enhanced 4DCT is planned..&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2021</start_date>
  <completion_date type="Anticipated">January 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the reproducibility of PBV DECT imaging and 4DCT derived lung ventilation for evaluating lung function</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>correlate changes of PBV DECT and 4DCT lung function images seen at ~6 months with radiation dose and with patient reported outcome quality of life</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>â€¢ To propose a novel biologic (i.e. functional) dose volume algorithm to reduce PBV and 4DCT lung function changes</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>contrast enhanced 4DCT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>contrast enhanced 4DCT</intervention_name>
    <description>Functional Lung Imaging with DECT and 4DCT</description>
    <arm_group_label>contrast enhanced 4DCT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients have histologic diagnosis of non-small cell lung cancer&#xD;
&#xD;
          -  Patients have AJCC stage III or IV disease were the plan is to receive definitive&#xD;
             concurrent chemoradiation to 60 Gy or higher&#xD;
&#xD;
          -  Age &gt; 18 years of age&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients have histologic diagnosis of non-small cell lung cancer&#xD;
&#xD;
          -  Patients have AJCC stage III or IV disease were the plan is to receive definitive&#xD;
             concurrent chemoradiation to 60 Gy or higher&#xD;
&#xD;
          -  Age &gt; 18 years of age&#xD;
&#xD;
          -  Patients are able to provide informed consent&#xD;
&#xD;
          -  No additional lung radiation is planned until after the 3rd CT on this study (i.e.&#xD;
             patient does not have a solitary pulmonary nodule or second primary that the plan is&#xD;
             to undergo SBRT)&#xD;
&#xD;
          -  Patient must have adequate kidney function to receive IV contrast (following&#xD;
             institutional policy supplied by radiology). The cutoff level for serum creatinine is&#xD;
             1.6 mg/dL&#xD;
&#xD;
          -  Negative urine pregnancy test before every CT scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to IV iodine contrast&#xD;
&#xD;
          -  Severe claustrophobia&#xD;
&#xD;
          -  Further thoracic radiation therapy is planned&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Feigenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Prendergast</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abamson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Prendergast</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Steven Feigenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

